Oxigene, Inc.
Records under this name other than patents Oxigene, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,877,967 | Compositions and methods for inhibition of cathepsins Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 9,458,103 | Compositions and methods for inhibition of cathepsins Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 9,873,668 | Compositions and methods for inhibition of cathepsins Formerly held Lapsed on the fee record Ended Jan 23, 2026 · From the USPTO record | Lapsed on the fee record | Ended Jan 23, 2026 | From the USPTO record |
| US 7,456,214 | Chromene-containing compounds with anti-tubulin and vascular targeting activity Formerly held Term ended Term ended Jan 30, 2025 · From the USPTO record | Term ended | Term ended Jan 30, 2025 | From the USPTO record |
| US 7,358,236 | Control of acute hypertension and cardiotoxicity in patients treated with vascular targeting agents Formerly held Term ended Term ended Nov 19, 2024 · From the USPTO record | Term ended | Term ended Nov 19, 2024 | From the USPTO record |
| US 8,198,302 | Compositions and methods with enhanced therapeutic activity Formerly held Lapsed on the fee record Ended Jun 12, 2024 · From the USPTO record | Lapsed on the fee record | Ended Jun 12, 2024 | From the USPTO record |
| US 9,040,500 | Method for treating hematopoietic neoplasms Formerly held Lapsed on the fee record Ended May 26, 2023 · From the USPTO record | Lapsed on the fee record | Ended May 26, 2023 | From the USPTO record |
| US 6,773,702 | Use of Combretastatin A4 and Its Prodrugs as an Immune Enhancing Therapy Formerly held Term ended Term ended Dec 26, 2021 · High confidence | Term ended | Term ended Dec 26, 2021 | High confidence |
| US 7,037,906 | Methods for Modulating Tumor Growth and Metastasis Formerly held Term ended Term ended Dec 20, 2021 · High confidence | Term ended | Term ended Dec 20, 2021 | High confidence |
| US 6,593,374 | Tubulin binding ligands and corresponding prodrug constructs Formerly held Term ended Term ended Jul 27, 2021 · From the USPTO record | Term ended | Term ended Jul 27, 2021 | From the USPTO record |